Standout Papers

T cells expressing CD19 chimeric antigen receptors for acute lymphoblast... 2010 2026 2015 2020 2.1k
  1. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial (2014)
    Daniel W Lee, James N. Kochenderfer et al. The Lancet
  2. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells (2011)
    James N. Kochenderfer, Mark E. Dudley et al. Blood
  3. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 (2010)
    James N. Kochenderfer, Wyndham H. Wilson et al. Blood
  4. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis (2010)
    Maria R. Parkhurst, James C. Yang et al. Molecular Therapy
  5. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma (2016)
    Syed Abbas Ali, Victoria Shi et al. Blood
  6. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response (2014)
    Paul F. Robbins, Sadik H. Kassim et al. Clinical Cancer Research
  7. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (2018)
    Nikolaos Zacharakis, Harshini Chinnasamy et al. Nature Medicine
  8. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma (2019)
    Stephanie L. Goff, Richard A. Morgan et al. Journal of Immunotherapy

Immediate Impact

9 by Nobel laureates 47 from Science/Nature 272 standout
Sub-graph 1 of 13

Citing Papers

CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
Principles and therapeutic applications of adaptive immunity
2024 Standout

Works of Steven A. Feldman being referenced

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
2014 Standout
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
2010 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Steven A. Feldman 9347 4600 2898 3059 85 11.1k
Hao Liu 9186 4215 3357 2789 87 11.1k
Martin Pulé 7016 3233 2663 2934 147 9.1k
Crystal L. Mackall 9385 4754 2463 3450 146 12.4k
Isabelle Rivière 8876 4211 3701 4079 156 11.8k
Cameron J. Turtle 8393 3732 2365 2937 162 11.4k
Michael Kalos 11484 5916 4049 4825 94 15.2k
Michael C. Milone 11138 5721 3439 4395 134 15.1k
Marcela V. Maus 9657 4734 3325 4801 199 13.3k
Laurence J.N. Cooper 7481 4616 2950 4194 230 11.1k
Terry J. Fry 8286 6091 2428 2697 188 12.8k

All Works

Loading papers...

Rankless by CCL
2026